Results 1 to 10 of about 13,707 (310)

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab [PDF]

New England Journal of Medicine, 2008
BACKGROUND The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause.
Frewer, Paul I. H., Gleich, Gerald J., Griffin, Elaine F., Haig, Ann E., Kahn, Jean E., Klion, Amy D., Parkin, Jacqueline M., Ring, Johannes, Rosenwasser, Lanny J., Rothenberg, Marc E., Roufosse, Florence E., Schwartz, Lawrence B., Simon, Hans-Uwe, Weller, Peter F.   +13 more
core   +9 more sources

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids.
Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD   +14 more
doaj   +3 more sources

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis [PDF]

BMC Pulmonary Medicine, 2019
Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance ...
Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +2 more sources

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE) [PDF]

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +2 more sources

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

Farmacia Hospitalaria, 2019
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin
Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo   +4 more
doaj   +5 more sources

Requalification of patients with severe asthma for biological therapy-Practical 'ReQuaBi' rate decision scheme based on the analytical model. [PDF]

Clin Transl Allergy
Abstract Background Patients with severe asthma experience decreased quality of life due to fixed airway obstruction, hospitalisations and potential fatalities. However, to date, the requalification of severe asthma patients eligible for biological therapy in daily clinical practice remains unstudied.
Majos A, Drissi AB, Kupczyk M, Panek M.
europepmc   +2 more sources

Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety [PDF]

, 2020
Introduction: Severe eosinophilic asthma is an incapacitating disease. Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, proved to be effective as an add-on therapy in patients with severe eosinophilic asthma.
Braunstahl, G.J. (Gert-Jan), Kappen, J.H. (Jasper H.), Toor, J.J. (Jermo) van, van der Mark, S.C. (Sophie C.), Veen, J.C.C.M. (Johannes) in 't   +4 more
core   +2 more sources

Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases [PDF]

Lung India
The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper ...
Dipti Gothi, Raghupathi Narasimhan, Randeep Guleria, Manu Chopra, Aanchal Gvalani, Rashmi Hegde   +5 more
doaj   +2 more sources

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab? [PDF]

Respiratory Medicine Case Reports
The efficacy of mepolizumab as an alternative to glucocorticoids for treating idiopathic chronic eosinophilic pneumonia (ICEP) has been reported. However, various questions remain unanswered, such as the most appropriate dose and dosage interval of ...
Masamitsu Hamakawa, Machiko Arita, Hiroshi Takahashi, Akihiko Amano, Nobuyoshi Hamao, Ayaka Tanaka, Akihiro Ito, Tadashi Ishida   +7 more
doaj   +2 more sources

Spending and Utilization for Chronic Rhinosinusitis With Nasal Polyps Therapies Among Commercially Insured Beneficiaries. [PDF]

Laryngoscope
The Food and Drug Administration (FDA) recently approved several novel therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP), though high prices may burden patients and payers. CRSwNP‐specific spending varied widely by prescription drug among commercially insured patients, ranging from $7050 (EDS‐FLU) to $28,324 (dupilumab).
Bhat AM, Schlosser RJ, Soler ZM, Rathi VK.   +3 more
europepmc   +2 more sources